PRMA Insights: The Roadmap to Pricing and Reimbursement Success

Scope of the metastatic breast cancer report

Comprehensive secondary research, experienced based insight and validation by payers and Key Opinion Leaders (KOLs) across markets underpins prmainsights™: The Roadmap to Pricing and Reimbursement Success in metastatic breast cancer:

In-depth coverage on the following sub-populations:

HER2+

HER2-

ER+

TNBC

 

Reporting of the regulatory indications and key supporting data for the following targeted therapies:

Avastin

Herceptin

Ixempra

Tyverb/Tykerb

 

Reporting of the regulatory indications and key supporting data for the following targeted therapies:

Hormonal therapies

Chemotherapies

 

The current pricing and reimbursement landscape for metastatic breast cancer in the Top 7 major pharmaceutical markets:

US

UK

France

Germany

Spain

Italy

Japan

 

Reviews of metastatic breast cancer clinical guidelines as published by:

NCCN

ESMO

NICE

St Gallen

Japan Breast Cancer Society

 

The comprehensive review and assessment of all pricing and reimbursement and HTA decisions for targeted
therapies and all relevant chemotherapeutic backbones for metastatic breast cancer across all lines of therapy.

The assessments of over 30 HTA and pricing and reimbursement decisions recently made in metastatic breast cancer by the following bodies:

AIFA	CEPS	CMS	DGFPS	G-BA	InEK	IQWiG
MHLW	NICE	SMC	TC	UVEF

Find out more about the metastatic breast cancer report:

The report delivers         Scope of the report        Authors of the report